Arianna Pina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Arianna Pina has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Cesare Gennari
Università degli Studi di Milano
5 shared publications - Daniela Arosio
Istituto di Scienze e Tecnologie Chimiche (SCITEC) ‘Giulio Natta’, Consiglio Nazionale Delle Ricerche (CNR), Via C. Golgi 19, Milan 20133, Italy
5 shared publications - Luca Pignataro
Università degli Studi di Milano
5 shared publications - Alberto Dal Corso
Università degli Studi di Milano
4 shared publications Michele Caruso
Nerviano Medical Sciences, Viale Pasteur, 10, I-20014, Nerviano, Italy
4 shared publications- André Raposo Moreira Dias
Dipartimento di Chimica Università degli Studi di Milano Via C. Golgi, 19 IT-20133 Milano Italy
3 shared publications
Latest Publications
- Open Access
- 19 November 2018
- Published by Wiley in Chemistry – A European Journal
- Vol. 25 (7) , 1696-1700
Neutrophil Elastase Promotes Linker Cleavage and Paclitaxel Release from an Integrin‐Targeted Conjugate
This work takes advantage of one of the hallmarks of cancer, that is, the presence of tumor infiltrating cells of the immune system and leukocyte‐secreted enzymes, to promote the activation of an anticancer drug at the tumor site. The peptidomimetic integrin ligand cyclo(DKP‐RGD) was found to accumulate on the surface of αvβ3 integrin‐expressing human renal cell carcinoma 786‐O cells. The ligand was conjugated to the anticancer drug paclitaxel through a Asn‐Pro‐Val (NPV) tripeptide linker, which is a substrate of neutrophil‐secreted elastase. In vitro linker cleavage assays and cell antiproliferative experiments demonstrate the efficacy of this tumor‐targeting conjugate, opening the way to potential therapeutic applications.
- 19 November 2018
- Published by Wiley in Chemistry – A European Journal
- Vol. 25 (7) , 1696-1700
Open AccessNeutrophil Elastase Promotes Linker Cleavage and Paclitaxel Release from an Integrin‐Targeted Conjugate
This work takes advantage of one of the hallmarks of cancer, that is, the presence of tumor infiltrating cells of the immune system and leukocyte‐secreted enzymes, to promote the activation of an anticancer drug at the tumor site. The peptidomimetic integrin ligand cyclo(DKP‐RGD) was found to accumulate on the surface of αvβ3 integrin‐expressing human renal cell carcinoma 786‐O cells. The ligand was conjugated to the anticancer drug paclitaxel through a Asn‐Pro‐Val (NPV) tripeptide linker, which is a substrate of neutrophil‐secreted elastase. In vitro linker cleavage assays and cell antiproliferative experiments demonstrate the efficacy of this tumor‐targeting conjugate, opening the way to potential therapeutic applications.
- Open Access
- 6 September 2017
- Published by Wiley in Chemistry – A European Journal
- Vol. 23 (58) , 14410-14415
Multivalency Increases the Binding Strength of RGD Peptidomimetic‐Paclitaxel Conjugates to Integrin αVβ3
This work reports the synthesis of three multimeric RGD peptidomimetic‐paclitaxel conjugates featuring a number of αVβ3 integrin ligands ranging from 2 to 4. These constructs were assembled by conjugation of the integrin αVβ3 ligand cyclo[DKP‐RGD]‐CH2NH2 with paclitaxel via a 2′‐carbamate with a self‐immolative spacer, the lysosomally cleavable Val‐Ala dipeptide linker, a multimeric scaffold, a triazole linkage, and finally a PEG spacer. Two monomeric conjugates were also synthesized as reference compounds. Remarkably, the new multimeric conjugates showed a binding affinity for the purified integrin αVβ3 receptor that increased with the number of integrin ligands (reaching a minimum IC50 value of 1.2 nm for the trimeric), thus demonstrating that multivalency is an effective strategy to strengthen the ligand–target interactions.
- 6 September 2017
- Published by Wiley in Chemistry – A European Journal
- Vol. 23 (58) , 14410-14415
Open AccessMultivalency Increases the Binding Strength of RGD Peptidomimetic‐Paclitaxel Conjugates to Integrin αVβ3
This work reports the synthesis of three multimeric RGD peptidomimetic‐paclitaxel conjugates featuring a number of αVβ3 integrin ligands ranging from 2 to 4. These constructs were assembled by conjugation of the integrin αVβ3 ligand cyclo[DKP‐RGD]‐CH2NH2 with paclitaxel via a 2′‐carbamate with a self‐immolative spacer, the lysosomally cleavable Val‐Ala dipeptide linker, a multimeric scaffold, a triazole linkage, and finally a PEG spacer. Two monomeric conjugates were also synthesized as reference compounds. Remarkably, the new multimeric conjugates showed a binding affinity for the purified integrin αVβ3 receptor that increased with the number of integrin ligands (reaching a minimum IC50 value of 1.2 nm for the trimeric), thus demonstrating that multivalency is an effective strategy to strengthen the ligand–target interactions.
- 12 June 2017
- Published by Wiley in ChemistrySelect
- Vol. 2 (17) , 4759-4766
Targeting Integrin α V β 3 with Theranostic RGD‐Camptothecin Conjugates Bearing a Disulfide Linker: Biological Evaluation Reveals a Complex Scenario
Theranostic RGD‐camptothecin conjugates, possessing a disulfide linker and a fluorescent naphthalimide moiety, were synthesized and biologically evaluated. The conjugates showed nanomolar affinity for the purified α V β 3 ‐integrin receptor. For antiproliferative assays, the U87 human glioblastoma were chosen as α V β 3 ‐expressing cells, whereas a non α V β 3 ‐expressing clone (U87 β 3 ‐KO) was generated as negative control. Although the U87 β 3 ‐KO cells treated with the conjugates showed a statistically significant reduced fluorescence intensity (in the range 7–12 %) compared to the parental U87, internalization of the conjugates was clearly observed in both cell lines. Stability studies showed premature cleavage of the disulfide linker in the cell media, with consequent release of free camptothecin. Consistent with the results of the internalization and stability studies, the conjugates did not show significant selectivity against the U87 cells compared to the U87 β 3 ‐KO clone.
- 12 June 2017
- Published by Wiley in ChemistrySelect
- Vol. 2 (17) , 4759-4766
Targeting Integrin α V β 3 with Theranostic RGD‐Camptothecin Conjugates Bearing a Disulfide Linker: Biological Evaluation Reveals a Complex Scenario
Theranostic RGD‐camptothecin conjugates, possessing a disulfide linker and a fluorescent naphthalimide moiety, were synthesized and biologically evaluated. The conjugates showed nanomolar affinity for the purified α V β 3 ‐integrin receptor. For antiproliferative assays, the U87 human glioblastoma were chosen as α V β 3 ‐expressing cells, whereas a non α V β 3 ‐expressing clone (U87 β 3 ‐KO) was generated as negative control. Although the U87 β 3 ‐KO cells treated with the conjugates showed a statistically significant reduced fluorescence intensity (in the range 7–12 %) compared to the parental U87, internalization of the conjugates was clearly observed in both cell lines. Stability studies showed premature cleavage of the disulfide linker in the cell media, with consequent release of free camptothecin. Consistent with the results of the internalization and stability studies, the conjugates did not show significant selectivity against the U87 cells compared to the U87 β 3 ‐KO clone.
- Open Access
- 26 May 2017
- Published by Wiley in Chemistry – A European Journal
- Vol. 23 (33) , 7910-7914
Tumor Targeting with an isoDGR–Drug Conjugate
Herein we report the first example of an isoDGR–drug conjugate (2), designed to release paclitaxel selectively within cancer cells expressing integrin αVβ3. Conjugate 2 was synthesized by connecting the isoDGR peptidomimetic 5 with paclitaxel via the lysosomally cleavable Val–Ala dipeptide linker. Conjugate 2 displayed a low nanomolar affinity for the purified integrin αVβ3 receptor (IC50=11.0 nm). The tumor targeting ability of conjugate 2 was assessed in vitro in anti‐proliferative assays on two isogenic cancer cell lines characterized by different integrin αVβ3 expression: human glioblastoma U87 (αVβ3+) and U87 β3‐KO (αVβ3−). The isoDGR‐PTX conjugate 2 displayed a remarkable targeting index (TI=9.9), especially when compared to the strictly related RGD‐PTX conjugate 4 (TI=2.4).
- 26 May 2017
- Published by Wiley in Chemistry – A European Journal
- Vol. 23 (33) , 7910-7914
Open AccessTumor Targeting with an isoDGR–Drug Conjugate
Herein we report the first example of an isoDGR–drug conjugate (2), designed to release paclitaxel selectively within cancer cells expressing integrin αVβ3. Conjugate 2 was synthesized by connecting the isoDGR peptidomimetic 5 with paclitaxel via the lysosomally cleavable Val–Ala dipeptide linker. Conjugate 2 displayed a low nanomolar affinity for the purified integrin αVβ3 receptor (IC50=11.0 nm). The tumor targeting ability of conjugate 2 was assessed in vitro in anti‐proliferative assays on two isogenic cancer cell lines characterized by different integrin αVβ3 expression: human glioblastoma U87 (αVβ3+) and U87 β3‐KO (αVβ3−). The isoDGR‐PTX conjugate 2 displayed a remarkable targeting index (TI=9.9), especially when compared to the strictly related RGD‐PTX conjugate 4 (TI=2.4).